CN108404111A - One kind is with kidney bean phytolectin inhibitory anti-virus preparation as main component - Google Patents

One kind is with kidney bean phytolectin inhibitory anti-virus preparation as main component Download PDF

Info

Publication number
CN108404111A
CN108404111A CN201711423419.8A CN201711423419A CN108404111A CN 108404111 A CN108404111 A CN 108404111A CN 201711423419 A CN201711423419 A CN 201711423419A CN 108404111 A CN108404111 A CN 108404111A
Authority
CN
China
Prior art keywords
kidney bean
gram
phytolectin
antibacterial
agglutinin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201711423419.8A
Other languages
Chinese (zh)
Other versions
CN108404111B (en
Inventor
王敏康
赵红
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yunnan Kangzhou Biological Science & Technology Co Ltd
Original Assignee
Yunnan Kangzhou Biological Science & Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yunnan Kangzhou Biological Science & Technology Co Ltd filed Critical Yunnan Kangzhou Biological Science & Technology Co Ltd
Priority to CN201711423419.8A priority Critical patent/CN108404111B/en
Publication of CN108404111A publication Critical patent/CN108404111A/en
Application granted granted Critical
Publication of CN108404111B publication Critical patent/CN108404111B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

One kind belonging to technical field of pharmaceuticals with kidney bean phytolectin inhibitory anti-virus preparation as main component.The relative weight share of each active component is:0.1~1.0 part of kidney bean phytolectin, one or both of stachyose, raffinose one or more in totally 0.2~2.0 part and following active components:0.1~0.5 part of povidone iodine, 0.1~0.3 part of poly hexamethylene biguanide, 0.1~0.5 part of Chlorhexidine；In addition, if desired thickener, then thickener is hydroxyethyl cellulose.Instant component is clear, can quantify and control, it is ensured that the consistent and stabilization of total quality, can be right, and bacterium, fungi and virus play specific inhibiting effect, and antibacterial and antiviral range are wider；Product need not preserve at low temperature, and the resting period is long, easy to use.

Description

One kind is with kidney bean phytolectin inhibitory anti-virus preparation as main component
Technical field
The invention belongs to technical field of pharmaceuticals.
Background technology
Currently, the sexually transmitted disease (STDs) including HIV causes prodigious threat to people's physical and mental health, and resist Also drug-fast bacteria occurs the abuse of rhzomorph extensively again.For viral disease, people's problem encountered is that viral species are numerous More, some virus-virus variations are fast, such as since inhibition of HIV variation is very fast, never ideal for many years to be effectively directed to HIV Vaccine occur.There is an urgent need to broad-spectrum antiseptic and antiviral, simple preparation be used to carry out daily protection and treatment.It burns The general wound such as wound, frostbite, knife wound, scratch, contusion, it is fine with iodophor disinfection effect.Due to compared with the tincture of iodine, alcohol, Iodophor Caused stimulation pain is slighter, is easy to be received by patient, and widely used, definite effect, substantially instead of alcohol, red The skin and mucous membrane disinfections agent such as mercury, the tincture of iodine, gentian violet.
Polyhexamethylene guanide broad-spectrum, effective concentration is low, work fast, and property is stablized, soluble easily in water, can be in room temperature Lower use, long-term antibacterial, without side-effects, non-corrosive, colourless, odorless, nontoxic, non-ignitable not quick-fried, moderate cost safe to use, fortune Defeated convenience, it may be said that be best fungicide.In fact, the product is a kind of environment-friendly multipurpose new polymers, industry, There is extremely extensive purposes in agriculture, medical and daily life.The product is cationic polymer, and antibacterial action is mainly By solubilizing lipids, change the permeability of bacterial cell membrane, endobacillary metabolism is made to occur obstacle and antibacterial.Its antimicrobial spectrum compared with Extensively, to Gram-positive and negative bacterium and mould effective force, have it is colourless, odorless, to no skin irritation, nontoxicity, without corruption The characteristics of corrosion, through its treated wet tissue, can Quick disinfection and will produce go mouldy, the shelf-life was up to 2 years.
Chlorhexidine also known as chlorohexidene, the entitled chlorhexidine of chemistry, cation surfactant have quite strong Broad-spectrum antibacterial, bactericidal effect, be a kind of preferable sterilizing medicine, the antibacterial action ratio benzene of Grain-positive and negative bacterium pricked Bromine ammonium is strong.Its band positive electricity, oral cavity containing gargle when be adsorbed on negatively charged patch and oral mucosal surface, the drug then adsorbed From these position disperses, gradually it is precipitated and generates lasting effect, until concentration reduces in saliva after 24 hours, be adsorbed on bacterium The permeability barrier of endochylema film, makes cellular content leak out, and is in bacteriostasis when low concentration, and when high concentration is in bactericidal effect, even if It is still valid in the presence ofs having serum, blood etc., few local irritations and allergic reaction.Chlorhexidine is that biguanides are efficient, wide Fungicide is composed, plays bactericidal effect by changing bacterial cytoplasm membrane permeability, bactericidal effect is better than quaternaries cation table Face activating agent is better than negative bacterium to gram positive bacteria effect, also effective to pseudomonas aeruginosa, fungi, but to acid fast bacteria, brood cell And virus is invalid.
Disclosing one kind application No. is 2013100565888 Chinese patent document, " kidney bean phytolectin is preparing people With in drug application and its pharmaceutical composition ", the drug is with kidney bean phytolectin, tremella polysaccharides, stachyose or/and cottonseed Sugar, Bletilla glucomannan, or it is active component to be further added by radix scutellariae, barberry and shrubby sophora extract, product need not be preserved, be deposited at low temperature It is long to put the time, easy to use, but its antibacterial, anti-virus ability and quality stability also need to further increase.
Invention content
The purpose of the present invention is to provide one kind with kidney bean phytolectin inhibitory anti-virus preparation as main component, and The prior art is compared, and need not only be preserved at low temperature, and the resting period is long, easy to use and its antibacterial, anti-virus ability It is stronger, it is easy to control quality.
The relative weight share of each active component is in invention formulation:0.1~1.0 part of kidney bean phytolectin, wood Sugar, one or both of raffinose one or more in totally 0.2~2.0 part and following active components:Povidone 0.1~0.5 part of iodine, 0.1~0.3 part of poly hexamethylene biguanide, 0.1~0.5 part of Chlorhexidine；In addition, if desired thickener, then increase Thick dose is hydroxyethyl cellulose.
Described kidney bean phytolectin can be navy bean phytolectin, can also be red kidney bean phytolectin.
It is difficult to match with most thickeners since the chemical property of various active components in invention formulation is different It closes, by largely screening and combining, we finally determine that hydroxyethyl cellulose can cooperate with use with mentioned component, and will not change The chemical property of each active component and the bioactivity of agglutinin.
Described povidone iodine, poly hexamethylene biguanide, Chlorhexidine are pharmaceutical grade product.
The dosage form of invention formulation can be water-soluble complex liquid or gelling agent, can also be solid dosage forms such as suppository, Sustained release agent, disintegrated tablet etc. are suitable for external application or vagina, the pharmaceutical dosage form of rectum.
Invention formulation is mainly external application, is played to body surface or the bacillary of mucous membrane, fungoid and viral infection Preventive and therapeutic effect, it can also be used to the prevention of other illness of human body, such as wound treatment, also act as and do contraceptive.
Invention formulation then contains following component if coagulant liquid in 100ml coagulant liquids:
0.5~1.0 gram of kidney bean phytolectin,
Totally 0.5~2.0 gram of one or both of stachyose, raffinose,
0.1~0.5 gram of povidone iodine,
0.1~0.3 gram of poly hexamethylene biguanide,
0.1~0.5 gram of Chlorhexidine,
0.8~0.9 gram of NaCl,
PH buffer is pharmaceutically coagulant liquid acceptable amount,
Stabilizer is pharmaceutically coagulant liquid acceptable amount,
Thickener：1.2~2.0 grams of hydroxyethyl cellulose.
Invention formulation then contains following component if liquid in 100ml preparation liquids:
0.1~1.0 gram of kidney bean phytolectin,
Totally 0.5~2.0 gram of one or both of stachyose, raffinose,
0.1~0.5 gram of povidone iodine,
0.1~0.3 gram of polyhexamethylene list guanidine or biguanides,
0.1~0.5 gram of Chlorhexidine,
0.8~0.9 gram of NaCl,
PH buffer is pharmaceutically coagulant liquid acceptable amount,
Stabilizer is pharmaceutically coagulant liquid acceptable amount.
Medicaments compound is the pathological state for body, emphasizes organic cooperation of each component and dosage, carries out multiple location, Suiting the medicine to the illness for different situations uses.
Inventive gel liquid can use in this way:With liquid or by 1:10 or 1:100~200 convert warm water or physiological saline into Outside row wound or vagina and introitus is cleaned, and is then smeared using gelling agent.
Outside can use liquid dosage form, vagina or anus/rectum to use gelling agent when using.
Kidney bean agglutinin used is navy bean or red kidney bean phytolectin in following experiment and embodiment.It is described solidifying Collection element produces white rue using the patented technology (application No. is 200910094233.1) authorized by applicant from Yunnan It is extracted in beans and red kidney bean.
The antibacterial action of product of the present invention is by selecting with clear bacteriostasis and with long-time service history and quilt It is proved to be chemical bacteriostatic agent povidone iodine effectively and safely, poly hexamethylene biguanide, Chlorhexidine combination are realized.What is used It can adjust the ratio of heterogeneity in concentration range.For example, to prepare the gel of the shallower anti-bacteriostasis of color, can adopt simultaneously With three kinds of bacteriostatic agents, the minimum concentration that at this moment can use three kinds of ingredients respectively takes 0.1%, i.e. 0.1 gram of povidone iodine, polyhexamethylene 0.1 gram of single guanidine or biguanides, 0.1 gram of Chlorhexidine, the summations of such three kinds of ingredients are that can prepare after 0.3 gram, with other components matchings The gel or liquid antibacterial liquid of 100ml；It is the two of 0.15~0.2 gram if using two kinds of ingredients, needing each ingredient Kind single component is composed, i.e., two kinds of antibacterial and total amounts that the gel of 100ml or liquid need are not less than 03-0.4 grams；If If only a kind of bacteriostatic agent of application is prepared, then the single antipathogenic composition that the gel of 100ml or liquid need is 0.5 gram, can Reach the antibacterial or fungistatic effect of 95-100%.The antivirus action of preparation is usually completed by adding kidney bean plant lectin 's.Reach facedown virus by the direct effect of kidney bean phytolectin and indirectly-acting or by enhancing the immune of body Ability has the function that antibacterial and antiviral.In addition, due to sugared binding characteristic possessed by agglutinin, and previous research institute's card Bright the characteristics of being aggregated blood and sperm, said preparation is in intravaginal using also having the function of practising contraception.Other beneficial effects are also It shows：
1. phytolectin is a kind of mitogen, cell division can be promoted in low concentration and to wound healing Play facilitation.
2. also containing estrogen kidney bean isoflavones, related studies have shown that both domestic and external in kidney bean phytolectin extracting solution Senile vaginitis patients can reverse the atrophy of vaginal wall to change and alleviate symptom using estrogen, and the supplement of estrogen increases The elasticity of the thickness of vagina epithelium, vaginal wall, reduces vaginal pH, has restored the self purification of vagina；
3. in addition to activated T lymphocytes, kidney bean agglutinin can also stimulate bone-marrow-derived lymphocyte to generate interferon and interleukins Deng raising humoral immunity level.
4. our previous results of study show that by vagina and rectal administration kidney bean agglutinin T lymphs can be improved Transformation rate.
Invention product is suitable for skin or mucous membrane wound, bacillary or viral infection.
Beneficial effects of the present invention:Compared to the prior art, instant component is clear, can quantify and control, it is ensured that is whole The consistent and stabilization of quality, can be right, and bacterium, fungi and virus play specific inhibiting effect, and antibacterial and antiviral range are wider； Product need not preserve at low temperature, and the resting period is long, easy to use.
Experiment 7 below is it is also shown that invention formulation is aggregated agglutination time of the time than independent agglutinin to red blood cell It substantially reduces, this is unexpected one of advantageous effect.
Extraction, purifying and the determination of activity of the agglutinins such as experiment 1, navy bean.
(1) extraction and purifying of the agglutinins such as navy bean or red kidney bean are using application No. is 200910094233.1 China Technology disclosed in patent document carries out, and protein content is measured using general double vena contracta methods.
(2) activity of lectin is measured using the technology disclosed in the Chinese patent document application No. is 201110184061.4 It carries out.
The inhibiting effect of experiment 2, kidney bean agglutinin and chemical bacteriostatic agent combination gel to Escherichia coli
One, equipment
1. bacterial strain:The 8099, the 5th~6 generation of Escherichia coli, by China Committee for Culture Collection of Microorganisms's common micro-organisms Center provides.
2. test specimen:The antibacterial lubricating gel of kidney bean agglutinin, date of manufacture or lot number August in 2015 15 days.
Two, method
1. GB15979-2002 is pressed in experiment《Disposable Sanitary Accessory sanitary standard》" stripping property resists (suppression) to appendix C 4 Bacterium product bacteriostasis property test method " carries out.
2. using the antibacterial lubricating gel Escherichia coli stoste of kidney bean agglutinin, 2min, 5min are acted on to Escherichia coli respectively, LOmin, 20min, experiment are repeated 3 times under the conditions of 1 DEG C of 20 scholar.
Three, result
Under the conditions of 1 DEG C of 20 scholar, repeatedly test result shows three times:The antibacterial lubricating gel stoste of kidney bean agglutinin is to large intestine Bacillus acts on 2min, and average bacteriostasis rate is 100.00%, as a result be see the table below:
Bacteriostasis of the antibacterial lubricating gel stoste of kidney bean agglutinin to Escherichia coli
Four, conclusion
The antibacterial lubricating gel stoste of kidney bean agglutinin acts on 2min to Escherichia coli, and average bacteriostasis rate is 100.00%, is pressed GB15979-2002《Disposable Sanitary Accessory sanitary standard》Evaluation criterion, the product stoste have stronger suppression to Escherichia coli Bacterium acts on.
The inhibiting effect of experiment 3, kidney bean agglutinin and chemical bacteriostatic agent combination gel to staphylococcus aureus
One, equipment
1. bacterial strain:Staphylococcus aureus ATCC6538, the 5th~6 generation, by China Committee for Culture Collection of Microorganisms Common micro-organisms center provides.
2. test specimen:The antibacterial lubricating gel of kidney bean agglutinin, date of manufacture or lot number August in 2015 15 days.
Two, method
1. GB15979-2002 is pressed in experiment《Disposable Sanitary Accessory sanitary standard》" stripping property resists (suppression) to appendix C 4 Bacterium product bacteriostasis property test method " carries out.
2. using the antibacterial lubricating gel staphylococcus aureus liquid of kidney bean agglutinin, staphylococcus aureus is acted on respectively 2min, 5min, 10min.20min, experiment are repeated 3 times under the conditions of 20 ± 10 DEG C.
Three, result
Under the conditions of 1 DEG C of 20 scholar, repeatedly test result shows three times:The antibacterial lubricating gel stoste of kidney bean agglutinin is to golden yellow Color staphylococcus acts on 2min, and average bacteriostasis rate is 100.00%, as a result be see the table below:
Bacteriostasis of the antibacterial lubricating gel stoste of kidney bean agglutinin to staphylococcus aureus
Four, conclusion
The antibacterial lubricating gel stoste of kidney bean agglutinin acts on 2min to staphylococcus aureus, and average bacteriostasis rate is 100.00%, by GB15979-2002《Disposable Sanitary Accessory sanitary standard》Evaluation criterion, the product stoste is to golden yellow Color staphylococcus has stronger bacteriostasis.
The inhibiting effect of experiment 4, kidney bean agglutinin and chemical bacteriostatic agent combination gel to Candida albicans
One, equipment
1. bacterial strain:Candida albicans ATCC10231, it is the 5th~6 generation, general by China Committee for Culture Collection of Microorganisms Logical microorganism center provides.
2. test specimen:The antibacterial lubricating gel of kidney bean agglutinin, date of manufacture or lot number August in 2015 15 days.
Two, method
1. GB15979-2002 is pressed in experiment《Disposable Sanitary Accessory sanitary standard》" stripping property resists (suppression) to appendix C 4 Bacterium product bacteriostasis property test method " carries out.
2, with the antibacterial lubricating gel Candida albicans bacterium stoste of kidney bean agglutinin, Candida albicans is acted on respectively 2min.5min, lOmin, 20min, experiment are repeated 3 times under the conditions of 1 DEG C of 20 scholar.
Three, result
Under the conditions of 1 DEG C of 20 scholar, repeatedly test result shows three times:The antibacterial lubricating gel stoste of kidney bean agglutinin is to white Candida albicans acts on 2min, and average bacteriostasis rate is 100.00%, as a result be see the table below:
Bacteriostasis of the antibacterial lubricating gel stoste of kidney bean agglutinin to Candida albicans
Four, conclusion
The antibacterial lubricating gel stoste of kidney bean agglutinin acts on 2min to Candida albicans, and average bacteriostasis rate is 100.0096, By GB15979-2002《Disposable Sanitary Accessory sanitary standard》Evaluation criterion, the product stoste to Candida albicans have compared with Strong bacteriostasis.
The stability experiment of experiment 5, kidney bean agglutinin and chemical bacteriostatic agent combination gel biocidal property
Above-mentioned gelling agent preserves 90 days under the conditions of 37 DEG C, and fungistatic effect is examined respectively with the method for experiment 2~4.
One, equipment
1. bacterial strain:Escherichia coli 8099 (the 5th~6 generation), staphylococcus aureus ATCC6538 (the 5th~6 generation), white are read Pearl bacterium ATCC10231 (the 5th~6 generation), is provided by China Committee for Culture Collection of Microorganisms's common micro-organisms center.
2. test specimen:The antibacterial lubricating gel of kidney bean agglutinin, date of manufacture or lot number August in 2015 15 days.
Two, method
1. GB15979-2002 is pressed in experiment《Disposable Sanitary Accessory sanitary standard》6 " stability test sides of appendix C Method carries out.
2. stability test, after the antibacterial lubricating gel of kidney bean agglutinin is preserved 90 days under the conditions of 37 DEG C, with its stoste Bacteriostasis 2min, 5min, lOmin, 20min are distinguished to Escherichia coli, staphylococcus aureus, Candida albicans, experiment exists It is repeated 3 times under the conditions of 20 DEG C ± 10 DEG C.
Three, result
Under the conditions of 20 DEG C ± 1 DEG C, repeatedly test result shows three times:The antibacterial lubricating gel of kidney bean agglutinin is through 37 DEG C of items Under part, after preserving 90 days, stoste acts on 2min, 5min to Escherichia coli, staphylococcus aureus, Candida albicans, LOmin, 20min, average bacteriostasis rate is 100.00%, as a result see the table below 1~3.
Bacteriostasis of the antibacterial lubricating gel of kidney bean agglutinin to Escherichia coli after table 1 is kept the temperature
Bacteriostasis of the antibacterial lubricating gel of kidney bean agglutinin to staphylococcus aureus after table 2 is kept the temperature
Bacteriostasis of the antibacterial lubricating gel stoste of kidney bean agglutinin to Candida albicans after table 3 is kept the temperature
Four, conclusion
The antibacterial lubricating gel of kidney bean agglutinin is through under the conditions of 37 DEG C, after preserving 90 days, stoste is to Escherichia coli, golden yellow Staphylococcus, Candida albicans act on 2min, 5min, l0min, 20min, and average bacteriostasis rate is 100.00%, the product Bacteriostasis can at least be kept 2 years at room temperature.
Experiment 6, the multiple vaginal mucomembranous irritant test of kidney bean agglutinin chemistry bacteriostatic agent combination gel
1, test material and method
(1) tested material:The antibacterial lubricating gel of kidney bean agglutinin.Test group:Sample is used as tested material as former state；Control group:It goes out Bacterium physiological saline.
(2) animal:She draws rabbit 4, regular grade to be provided by Kunming Chu Shang Science and Technology Ltd.s, animal quality certification number:SCXK (Yunnan) K2012-00020 feeds are provided by Kunming Chu Shang Science and Technology Ltd.s, quality certification number:SCXK (Yunnan) K2012-0003.Body It is without exception to look into animal.
(3) environmental condition:20-23 DEG C of temperature, relative humidity 40%~60%.Facility card number:SYXK (Yunnan) K2015- 0004。
(4) test method:According to the Ministry of Public Health《Disinfection technology standard》(version in 2002) 2.3.5 vaginal mucomembranous irritant tests. Experiment sets tested material group and negative control group, every group of 3 animals.Animal is faced upward fixation, perineum and introitus are exposed.It will lead It is effective moistened by test solution after be gently inserted into vagina 5cm, be used in combination syringe to be slowly injected into 2mL tested materials.Control animals are with going out Bacterium physiological saline makees same processing.Every primary, the continuous 5d that repeats to contaminate for 24 hours.After last contamination for 24 hours, it is put to death using aeroembolism method Animal cuts open the belly and takes out complete vagina, and longitudinally slit, whether have congested, oedema phenomena such as, vagina is put into 10% if visually observing It is fixed in formalin solution more than for 24 hours, chooses the tissue film-making at vagina both ends and central 3 positions and carry out group after HE dyeing Knit pathological examination.
2, test result
Gross anatomy:Have no apparent hyperemia, oedema, erosion.
The antibacterial lubricating gel vaginal mucosa irritation reaction scoring of beans agglutinin
Note:Average integral=stimulate the reaction integral is added divided by observation sum (observation sum=number of animals × 3).
Stimulus index=test group average integral-control group average integral=5.20-0.56=4.64
3, conclusion
Under this experiment condition, kidney bean agglutinin combination gel draws the multiple vaginal mucomembranous irritant test result of rabbit to comment her It is pole subexcite to divide by vaginal mucosa irritation strength grading standard determination.
Experiment 7, kidney bean agglutinin chemistry bacteriostatic agent combination gel test the agglutination of red blood cell
Above-mentioned gel is taken, adds balanced salt solution (PBS) to be diluted to the dilution of the 1mg/ml containing agglutinin, then uses PBS again Liquid carries out the dilution of doubling dilution to 1/256, is then respectively adding in preceding 8 hole of 9 orifice plates, and the 9th hole of 9 orifice plates is PBS pairs According to group.People or mouse blood PBS liquid and Washed Red Blood Cells are taken, the red blood cell liquid as 4% is then prepared.It is 1 by volume: 1 mode is added to 4% red blood cell liquid in 1~9 hole of 9 orifice plates.20~25 DEG C of room temperature is placed 60~120 minutes, is then seen Examine the agglutination situation in each hole.Test result shows agglutination activity between 1/128~1/256mg.It lives with independent kidney bean agglutinin Property it is identical, illustrate that this combination does not have any influence to agglutination activity, and is found that a new phenomenon is aggregated time ratio The agglutination occurred after individual agglutinin effect substantially reduces, and agglutination phenomenon occurs for agglutinin independent role generally at 60 minutes Afterwards, and gelling agent causes the time of red blood cell gel to may occur in which within 5 minutes after the reaction, i.e., gel reaction accelerate 10 times with On.U.S. Sigma-Aldrich is the maximum chemical reagent manufacturer in the whole world, and Sigma-Aldrich is a biology/chemistry examination The leading high-tech enterprise of agent.Agglutination activity is by Sigma-Aldrich's standard determination method： (Agglutination activity is expressed inμg/mL and is determined from serial dilutions of a 1mg/mL solution.This activity is the lowest concentration to Agglutinate a 2%suspension of human erythrocytes in phosphate buffered The 25 DEG C of sources saline, pH 6.8, after 1hr incubation at：http://www.sigmaaldrich.com/ catalog/product/sigma/l2646Lang=zh＆region=CN＆cm_sp=Insite--recent_ Fixed-_-recent5-1), that is, need the reaction by 1 hour that could judge the agglutination activity of (kidney bean) agglutinin.Pass through this Gel after method compounding highly shortened the agglutination time.Such result is extremely advantageous for the application of the combined gels, Such as in contraception, it can be quickly aggregated sperm, improve the contraceptive efficacy effect of the gelling agent；In terms of for wound hemostasis, Since it is quickly aggregated red blood cell, quick-acting haemostatic powder can be played the role of to the bleeding of small wound.
Experiment 8, kidney bean agglutinin chemistry bacteriostatic agent combination gel test sperm death and agglutination
This experiment is tested using people and dog sperm.Human spermatogoa is collected for healthy human body masturbation method, is suspended in EF solution [full pine, Zhou Haikuan, hill repair department, wait fertility [J] No.1 Military Medical Univ. of refrigerations human spermatogoa in electrolyte-free solution Journal, 2002,22 (10):928-930.], 4 DEG C of preservations, 1h is interior to be used.Dog sperm is that artificial semenpicking is same as above method preservation and makes With.
According to the methods of Sander-Cramer [[Bharitkar Y P, Banerjee M, Kumar S, et al.Search for a potent microbicidal spermicide from the isolates of Shorea Robusta resin [J] .Contraception, 2013,88 (1):133-140.], take 1 volume sperm respectively with 5 volumes not RKBL gelling agents with concentration are sufficiently mixed.That is 100 μ l sperm respectively with 500 μ l containing 5,2.5,1,0.5,0.25,0.1,0.05, 0.025, the xanthans gelling agent mixing of 0.01,0.005,0.0025,0.001 (mg/ml) RKBL, after rapid piping and druming uniformly, 5 μ l are respectively taken out in 20s, are × 100 microscopically observations in amplification factor, are observed again after 5min, if being observed after 5min 100% motile sperm is aggregated, then this result is final result, otherwise thereafter per 20min repeated observations, continuous observation 3 hours.Experiment is repeated 7 times.
Spermicidal and agglutination the experimental results showed that, the above-mentioned gelling agent of the agglutinin of kidney bean containing 5mg/ml can make essence in 20s Son inactivates, and when RKBL concentration contained by gelling agent is greater than or equal to 1mg/ml, sperm can be made to lose mobility in interior 20s, generates Braking and lethal effect, but do not generate agglutination phenomenon.And containing 0.5mg/ml, 0.25mg/ml, 0.1mg/ml, 0.05mg/ml, 0.025mg/ml, 0.01mg/ml RKBL gelling agent can make sperm generate agglutination phenomenon.When a concentration of 0.05mg/ml, essence Son agglutination is more than 50%.Checked and (2011, the 5th edition) sperms formulated for the treatment of of laboratory handbook according to WHO human seminal fluids Agglutination standard can effectively play contraception function.
Specific implementation mode
Embodiment 1：It is formulated A.Contain in 100 milliliters of coagulant liquids:
0.4~0.5 gram of navy bean phytolectin,
Oligosaccharide (total amount of stachyose and raffinose) 0.5g,
Chemical bacteriostatic agent：0.2~0.5 gram of povidone iodine,
Chemical bacteriostatic agent：0.1~0.3 gram of polyhexamethylene guanide,
Chemical bacteriostatic agent：0.1~0.3 gram of chlorhexidine acetate,
0.85 gram of NaCl,
PH buffer:For Acetic acid-sodium acetate buffer solution (pH4.5, takes 1.8 grams of sodium acetate, acetic acid 0.98m1 on the rocks,
Add water be diluted to 100ml to get,
Stabilizer:4,000 0.5~2.0 grams of PEG,
1.4~2.0 grams of thickener hydroxyethyl cellulose,
PH value is 4.3~4.8.
Embodiment 2：It is formulated B.Contain in 100 milliliters of coagulant liquids:
0.4~0.5 gram of red kidney bean phytolectin,
Oligosaccharide (total amount of stachyose and raffinose) 0.2~0.5g,
Chemical bacteriostatic agent：0.2~0.5 gram of povidone iodine,
Chemical bacteriostatic agent：0.1~0.3 gram of polyhexamethylene guanide,
0.7~0.85 gram of NaCl,
PH buffer:For Acetic acid-sodium acetate buffer solution, (pH4.5 takes 1.8 grams of sodium acetate, acetic acid 0.98m1 on the rocks, then adds Water be diluted to 100ml to get,
Stabilizer:4,000 0.5~2.0 grams of PEG,
1.2~2.0 grams of thickener hydroxyethyl cellulose
PH value is 4.3~4.8
Embodiment 3：Thickener is subtracted on the basis of being formulated A and B, is antibacterial (washing) liquid of kidney bean agglutinin chemistry.
0.4~0.5 gram of phytolectin,
0.3~0.5 gram of oligosaccharide,
Chemical bacteriostatic agent：0.2~0.5 gram of povidone iodine,
Chemical bacteriostatic agent：0.1~0.3 gram of polyhexamethylene guanide.
Embodiment 4, the bacteriostasis that two or three of bacteriostatic agent of various concentration is combined with agglutinin are detected using above-mentioned The strain and method, processing time 5min of experiment 2,3,4 are detected under conditions of 37.0 ± 1 DEG C.As a result following Table A, Shown in B, C.The result shows that above-mentioned bacteriostatic agent various combination, in 0.1%PHA, one or both of stachyose, raffinose exist altogether Bacteriostasis rate under 0.2% concentration can reach 95% or more.
A.0.1% inhibiting effect of the antibacterial profit liquid that kidney bean agglutinin is combined with other antipathogenic compositions to Escherichia coli
B.0.1% the antibacterial profit liquid that kidney bean agglutinin is combined with other antipathogenic compositions makees the inhibition of staphylococcus aureus With
C.0.1% inhibiting effect of the antibacterial profit liquid that kidney bean agglutinin is combined with other antipathogenic compositions to Candida albicans
Embodiment 5：To vagina itch, the therapeutic effects such as peculiar smell or the daily cleaning at man-female's vulva position nursing.First With the antibacterial liquid Direct spraying of embodiment 3 or vulva and introitus are smeared, or presses 1:00 or 1:200 warm waters exchange uniform, and cleaning is outer Private parts.Then it is pushed into the gelling agent that 2~5ml A or B are formulated to intravaginal.It is daily to use 1~2 time, abnormal leucorrhea can be reduced, it is right It is with obvious effects to eliminate the ill symptoms such as peculiar smell and itch.Above-mentioned gelling agent is actually used through tens of people, definite effect.
The simple antibacterial liquid for using embodiment 3, by 1:00 or 1:200 warm waters exchange uniform, and can be used for male genitals and woman The daily cleaning of female's vulva is nursed.
Embodiment 6：Lubrication and contraceptive efficacy.Due to being killed with high concentration to red blood cell and sperm, low concentration agglutination Effect, therefore A is used, B gelling agents can act as good lubrication and contraceptive efficacy.Experiment proof, agglutinin gelling agent Agglutinin concentration is in 1mg/ml~5mg/ml.With pressure bottle or gynaecology's propeller of 4.5~5.0g, vagina is sprayed on before sexual life Mouth is pushed into 4.5~5.0g with gynaecology's propeller.In September, 2015 in September, 2017, have more than 100 people used it is this novel Gel is used as lubrication and contraception, does not occur 1 failure.
Embodiment 7：The virus function of anti-bleb
In September, 2017 treats an example private parts herpes simplex virus.It is remaining so-and-so, women, perineum part occur Limitation gathering phlycten at one, tenderness, when treatment, first needle phlycten with 5# sterile injection syringe needles, are gently pressed as possible with disinfecting cotton swab Liquid is squeezed out, gel is then smeared, each primary daily morning and evening, continuous use was by 7 days, subsequent bleb position recovery from illness.
Embodiment 8：Therapeutic effect to ox and swine foot-and-mouth disease virus
The 5-7 months in 2016 treatment observation is carried out to ox and Schweineseuche in Yunnan Muller city and Yiliang County respectively, has been summarized It is as follows：
Dental care：Oral cavity is washed with 0.1%~0.2% liquor potassic permanganate or 2%~3% acetic acid or vinegar, so It gives afterwards on face of festering and smears gelling agent, smear every other day once, cooperation uses 1:100 with after normal saline dilution be added drinking-water in make Illness pig, ox take, and can receive positive effect within 8-14 days.Total effective rate is 85% or so.
Hoof is treated：Hoof is impregnated with 3%~5% copper-bath.It is smeared with gelling agent after dry, daily or every other day Once, cooperation uses 1:100 with normal saline dilution after be added drinking-water in so that illness pig, ox is taken, be used continuously 10-15 days energy See positive effect.Total effective rate is 80% or so.
Breast treatment：Routine disinfection, warm water cleaning is wanted then to be coated with gelling agent, daily or once every other day when milking.8-12 It can see positive effect.Total effective rate is 80% or so.The above processing ox number about 30, as a result pig about 50 shows Gelling agent treatment improves about 30% or more than the effective percentage of traditional therapy.

Claims (3)

1. one kind is with kidney bean phytolectin inhibitory anti-virus preparation as main component, it is characterised in that the phase of each active component It is to weight quota:0.1~1.0 part of kidney bean phytolectin, one or both of stachyose, raffinose totally 0.2~2.0 One or more in part and following active components:0.1~0.5 part of povidone iodine, poly hexamethylene biguanide 0.1~ 0.3 part, 0.1~0.5 part of Chlorhexidine.
2. as described in claim 1 with kidney bean phytolectin inhibitory anti-virus preparation as main component, it is characterised in that For coagulant liquid, following component is contained in 100ml coagulant liquids:
0.5~1.0 gram of kidney bean phytolectin,
Totally 0.5~2.0 gram of one or both of stachyose, raffinose,
0.1~0.5 gram of povidone iodine,
0.1~0.3 gram of poly hexamethylene biguanide,
0.1~0.5 gram of Chlorhexidine,
0.8~0.9 gram of NaCl,
PH buffer is pharmaceutically coagulant liquid acceptable amount,
Stabilizer is pharmaceutically coagulant liquid acceptable amount,
Thickener：1.2~2.0 grams of hydroxyethyl cellulose.
3. as described in claim 1 with kidney bean phytolectin inhibitory anti-virus preparation as main component, it is characterised in that For liquid, following component is contained in 100ml preparation liquids:
0.1~1.0 gram of kidney bean phytolectin,
Totally 0.5~2.0 gram of one or both of stachyose, raffinose,
0.1~0.5 gram of povidone iodine,
0.1~0.3 gram of polyhexamethylene list guanidine or biguanides,
0.1~0.5 gram of Chlorhexidine,
0.8~0.9 gram of NaCl,
PH buffer is pharmaceutically coagulant liquid acceptable amount,
Stabilizer is pharmaceutically coagulant liquid acceptable amount.
CN201711423419.8A 2017-12-25 2017-12-25 A bacteriostatic and antiviral preparation containing semen Phaseoli vulgaris phytohemagglutinin as main ingredient Active CN108404111B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711423419.8A CN108404111B (en) 2017-12-25 2017-12-25 A bacteriostatic and antiviral preparation containing semen Phaseoli vulgaris phytohemagglutinin as main ingredient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711423419.8A CN108404111B (en) 2017-12-25 2017-12-25 A bacteriostatic and antiviral preparation containing semen Phaseoli vulgaris phytohemagglutinin as main ingredient

Publications (2)

Publication Number Publication Date
CN108404111A true CN108404111A (en) 2018-08-17
CN108404111B CN108404111B (en) 2020-04-28

Family

ID=63125589

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711423419.8A Active CN108404111B (en) 2017-12-25 2017-12-25 A bacteriostatic and antiviral preparation containing semen Phaseoli vulgaris phytohemagglutinin as main ingredient

Country Status (1)

Country Link
CN (1) CN108404111B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110755601A (en) * 2019-10-31 2020-02-07 云南康洲生物科技有限公司 Kidney bean agglutinin plant medicine composition for treating HIV/AIDS immune reconstitution defect and preparation method and application thereof
CN111450235A (en) * 2020-06-05 2020-07-28 杨正东 Contraceptive gel jelly
CN113230205A (en) * 2021-05-22 2021-08-10 绍兴鸿瑞生物科技有限公司 Gynecological gel preparation and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101508730A (en) * 2009-03-18 2009-08-19 王敏康 Extract method for lectin of leguminous plants
CN103157095A (en) * 2013-02-22 2013-06-19 云南康洲生物科技有限公司 Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101508730A (en) * 2009-03-18 2009-08-19 王敏康 Extract method for lectin of leguminous plants
CN103157095A (en) * 2013-02-22 2013-06-19 云南康洲生物科技有限公司 Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
王昌梅等: "阴道或直肠注入芸豆植物凝集素的亚慢性实验研究", 《中国预防医学杂志》 *
郭春生等: "芸豆植物凝集素的提取及血凝效果研究", 《中国兽药杂志》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110755601A (en) * 2019-10-31 2020-02-07 云南康洲生物科技有限公司 Kidney bean agglutinin plant medicine composition for treating HIV/AIDS immune reconstitution defect and preparation method and application thereof
CN111450235A (en) * 2020-06-05 2020-07-28 杨正东 Contraceptive gel jelly
CN113230205A (en) * 2021-05-22 2021-08-10 绍兴鸿瑞生物科技有限公司 Gynecological gel preparation and preparation method and application thereof
CN113230205B (en) * 2021-05-22 2023-07-07 绍兴鸿瑞生物科技有限公司 Gynecological gel preparation and preparation method and application thereof

Also Published As

Publication number Publication date
CN108404111B (en) 2020-04-28

Similar Documents

Publication Publication Date Title
US11083689B2 (en) Lubricant formulations
CN107802825A (en) A kind of Traditional Chinese medicine gel composition antibacterial for vaginal mucosa
CN113081928B (en) Plant antibacterial gel and preparation method and application thereof
RU2308951C2 (en) Complex method for preventing vaginal dysbacteriosis (variants)
CN107998461A (en) A kind of sheath that is exclusively used in has the function of the soluble oil of composite antibacterial
CN108404111A (en) One kind is with kidney bean phytolectin inhibitory anti-virus preparation as main component
US10478463B2 (en) External-use medicament for cleaning and care of the ovaries, vagina, and vulva
CN101543658B (en) Cervical cap for preventing and treating cervical erosion and preparation method thereof
CN108324922A (en) A kind of gel combination of prevention and treatment gynaecological imflammation
AU2018248728B2 (en) Natural composition for use in gynaecology
CN106581320A (en) Preparation method of plant extract and preparation containing plant extract and used for women
CN111012902A (en) Female antibacterial contraception maintenance gel and preparation method thereof
CN106237029B (en) A kind of aloe antibiotic gel and preparation method thereof
CN105079000B (en) A kind of composition and its application, preparation
RU2401657C2 (en) Method of prevention and treatment of mastitis in cows
CN100388949C (en) Lysostaphin freeze dried powder used for preventing and treating cattle edometritis
CN103599437B (en) One treats colpitic traditional Chinese medicine liquid
KR101862628B1 (en) A composition of skin lubicant preparation and the method therefor
CN109453146A (en) Composition of resisting pathogenic microbes and its preparation method and application
US11857674B2 (en) Lubricant formulations
CN1462584A (en) Externally-used disinfector
EP3246015B1 (en) Lubricant formulations
CN102000282B (en) Pure traditional Chinese medicine paster for treating recurrent oral ulcer and preparation method thereof
CN106138206A (en) A kind of plant type milch cow special uterus washing liquid and preparation method thereof
RU2134572C1 (en) Antiseptic ointment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant